While driving local innovation, BD is also actively seeking strategic collaboration with local partners.
Firstly, BD signed a framework agreement on pharmacy dispensing robots with Hangzhou Zetian Chunlai Technology Co., Ltd. Under the agreement, the two companies will work closely with each other for local innovation and local manufacturing in a local ecosystem, and to serve the construction of smart pharmacies and smart hospitals in China in a faster, better and more pertinent manner. Meanwhile, BD also signed an agreement with Yadu Holdings Group for strategic collaboration project on innovative urine drainage solution. Through this project, BD wants to bring its groundbreaking female external catheters to China faster, so that local patients can benefit from this global medtech product as early as possible, while providing a strong driver for the company’s sustainable growth in China.
Prior to the inauguration of the GCTIC, BD had already signed agreements with the first Chinese customers for its latest RhapsodyTM HT Xpress System, a higher-throughput platform for analyzing single cells. This epoch-making single-cell multiomics analysis platform is able to run million cell studies easily. BD was able to sell 6 units of this system to Chinese customers when they formally saw the product for the first time after its launch.
In addition, after the opening of GCTIC, BD launched National Laboratory Competency Building and Quality Management Improvement Project, building specialized communication platform cooperated with national laboratory KOLs, College of American Pathologists, etc.